A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer

Trial Profile

A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs ONT 10 (Primary) ; Varlilumab (Primary)
  • Indications Advanced breast cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 29 Mar 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
    • 29 Mar 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 05 Nov 2015 Status changed from recruiting to discontinued, as per the Celldex Therapeutics Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top